REGENXBIO Inc (NASDAQ: RGNX) has reported a loss for its fourth fiscal quarter (ending December 31) of $-1.43 versus a loss $-1.38 for the same period a year ago. This result fell short of the consensus estimate of $-1.28 by $-0.15. For the latest four quarters through December 31, E.P.S. were $-6.02 versus $-6.50 for the same period a year ago.
Recent Price Action
REGENXBIO Inc (NASDAQ: RGNX) stock closed at $20.02 on 2/27/24 after a very large increase of 9.2%. Moreover, trading volume in this advance was unusually high at 151% of normal. The stock has risen 6.3% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
RGNX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
REGENXBIO has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. REGENXBIO has a poor Appreciation Score of 25 and a poor Power Rating of 20, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment